Enhancing the Patient Journey in Chronic inflammatory demyelinating polyneuropathy (CIDP): Strategies for Improved Detection and Individualized Management
Webcast
1 AMA PRA Category 1 Credit™ ...Faculty
OVERVIEW
Enhancing the Patient Journey in Chronic inflammatory demyelinating polyneuropathy (CIDP): Strategies for Improved Detection and Individualized Management is organized by i3 Health.
Dates Available:
November 18, 2025 - November 17, 2026
Statement of Need:
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, immune-mediated peripheral nerve disease characterized by progressive sensorimotor neuropathy (van Doorn et al, 2024). Patients with typical CIDP experience symmetric muscle weakness, sensory disturbances in the limbs, and reduction or loss of deep tendon reflexes. Other variants exist with differing clinical presentations. Patients with CIDP experience significant impacts of functioning and quality of life (Quint et al, 2025). While early diagnosis and treatment initiation may reduce the risk of permanent disability resulting from irreversible axonal damage, timely diagnosis is complicated by highly variable clinical presentations. In order to optimize outcomes for their patients, it is crucial for members of the interdisciplinary care team to remain up to date on advances in diagnostic criteria and tests; treatment approaches with immunoglobulin, corticosteroids, plasma exchange, and other therapies; and strategies for tailoring therapeutic selection to each patient’s individual situation (van Doorn et al, 2024). In this activity, Karissa Gable, MD, Professor of Neurology at Duke University Medical Center, will explore strategies for improved detection and individualized management to enhance the patient journey in CIDP.
Learning Objectives:
Upon completion of this activity, participants should be able to:
- Describe signs, symptoms, and assessments that can inform CIDP diagnosis
- Appraise guideline recommendations for CIDP induction and maintenance therapy
- Evaluate the safety and efficacy of current and emerging agents for the treatment of CIDP
- Assess strategies to tailor CIDP therapy based on patient needs, preferences, and therapeutic response
ACCREDITATION & CREDITS
Jointly Accredited Provider:
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians:
i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants/Associates:
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 11/17/26. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners:
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development:
A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.6 contact hours of pharmacology credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour.
Continuing Pharmacy Education:
i3 Health has approved this knowledge-based activity for 1.0 ACPE CE hour. The Universal Activity Number for this activity is JA0008128-0000-25-036-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion.
TARGET AUDIENCE
PhysicianNursingPharmacistPhysician AssistantNeurologistsNurse Practitioners Other Healthcare ProfessionalsSPECIALITIES
Chronic DiseasesNeurology
Download eMedEvents Mobile App
Track your CE certificates and CME requirements anytime, anywhere.
Quick Links